Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HCN1 | O60741 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31034935 | 1.00 | MME (0.41) | MMENPSR1HDAC9ADRA2AADRA2B | |
| SCHEMBL9527850 | 0.88 | ATM (0.40) | MMECETPATM | |
| SCHEMBL855127 | 0.82 | MME (0.42) | MMENPSR1HDAC9ADRA2AADRA2B | |
| SCHEMBL857043 | 0.82 | MME (0.46) | MMENPSR1HDAC9ADRA2AADRA2B | |
| SCHEMBL31034835 | 0.82 | MME (0.46) | MMENPSR1HDAC9ADRA2AADRA2B | |
| SCHEMBL31034910 | 0.81 | MME (0.41) | MMENPSR1HDAC9ADRA2AADRA2B | |
| SCHEMBL27796327 | 0.81 | MME (0.41) | MMENPSR1HDAC9ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL856898 | 0.81 | MME (0.45) | MMENPSR1HDAC9BRD4MMP8 | |
| SCHEMBL8856397 | 0.80 | CETP (0.43) | CETPALDH1A1CXCR5 | |
| SCHEMBL856751 | 0.78 | MME (0.40) | MMENPSR1HDAC9ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | CYP3A5, CYP3A4, IPO5 | MME 1522/4885NPSR1 3167/4885HDAC9 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.